SONN Relative Valuation
SONN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SONN is overvalued; if below, it's undervalued.
Historical Valuation
Sonnet Biotherapeutics Holdings Inc (SONN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -0.62. The fair price of Sonnet Biotherapeutics Holdings Inc (SONN) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：1.06
Fair
-0.36
PE
1Y
3Y
5Y
Trailing
Forward
-0.46
EV/EBITDA
Sonnet Biotherapeutics Holdings Inc. (SONN) has a current EV/EBITDA of -0.46. The 5-year average EV/EBITDA is -0.07. The thresholds are as follows: Strongly Undervalued below -0.46, Undervalued between -0.46 and -0.27, Fairly Valued between 0.12 and -0.27, Overvalued between 0.12 and 0.31, and Strongly Overvalued above 0.31. The current Forward EV/EBITDA of -0.46 falls within the Strongly Undervalued range.
-1.44
EV/EBIT
Sonnet Biotherapeutics Holdings Inc. (SONN) has a current EV/EBIT of -1.44. The 5-year average EV/EBIT is -0.32. The thresholds are as follows: Strongly Undervalued below -1.49, Undervalued between -1.49 and -0.90, Fairly Valued between 0.26 and -0.90, Overvalued between 0.26 and 0.85, and Strongly Overvalued above 0.85. The current Forward EV/EBIT of -1.44 falls within the Undervalued range.
21.16
PS
Sonnet Biotherapeutics Holdings Inc. (SONN) has a current PS of 21.16. The 5-year average PS is 79.67. The thresholds are as follows: Strongly Undervalued below -81.52, Undervalued between -81.52 and -0.93, Fairly Valued between 160.26 and -0.93, Overvalued between 160.26 and 240.86, and Strongly Overvalued above 240.86. The current Forward PS of 21.16 falls within the Historic Trend Line -Fairly Valued range.
-0.48
P/OCF
Sonnet Biotherapeutics Holdings Inc. (SONN) has a current P/OCF of -0.48. The 5-year average P/OCF is -0.24. The thresholds are as follows: Strongly Undervalued below -0.89, Undervalued between -0.89 and -0.56, Fairly Valued between 0.09 and -0.56, Overvalued between 0.09 and 0.42, and Strongly Overvalued above 0.42. The current Forward P/OCF of -0.48 falls within the Historic Trend Line -Fairly Valued range.
-1.00
P/FCF
Sonnet Biotherapeutics Holdings Inc. (SONN) has a current P/FCF of -1.00. The 5-year average P/FCF is -0.40. The thresholds are as follows: Strongly Undervalued below -1.85, Undervalued between -1.85 and -1.13, Fairly Valued between 0.32 and -1.13, Overvalued between 0.32 and 1.05, and Strongly Overvalued above 1.05. The current Forward P/FCF of -1.00 falls within the Historic Trend Line -Fairly Valued range.
Sonnet Biotherapeutics Holdings Inc (SONN) has a current Price-to-Book (P/B) ratio of -1.38. Compared to its 3-year average P/B ratio of -0.64 , the current P/B ratio is approximately 116.24% higher. Relative to its 5-year average P/B ratio of 1.59, the current P/B ratio is about -186.77% higher. Sonnet Biotherapeutics Holdings Inc (SONN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -263.03%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -208.22% , the current FCF yield is about -100.00% lower.
-1.38
P/B
Median3y
-0.64
Median5y
1.59
-48.72
FCF Yield
Median3y
-263.03
Median5y
-208.22
Competitors Valuation Multiple
The average P/S ratio for SONN's competitors is 0.00, providing a benchmark for relative valuation. Sonnet Biotherapeutics Holdings Inc Corp (SONN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SONN decreased by 13.70% over the past 1 year. The primary factor behind the change was an decrease in Revenue Growth from 0.00 to 0.00.
The secondary factor is the Margin Expansion, contributed -95.49%to the performance.
Overall, the performance of SONN in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Sonnet Biotherapeutics Holdings Inc (SONN) currently overvalued or undervalued?
What is Sonnet Biotherapeutics Holdings Inc (SONN) fair value?
How does SONN's valuation metrics compare to the industry average?
What is the current P/B ratio for Sonnet Biotherapeutics Holdings Inc (SONN) as of Dec 05 2025?
What is the current FCF Yield for Sonnet Biotherapeutics Holdings Inc (SONN) as of Dec 05 2025?
What is the current Forward P/E ratio for Sonnet Biotherapeutics Holdings Inc (SONN) as of Dec 05 2025?